coin-img-ETHETH-1.67%coin-img-BTCBTC-0.32%coin-img-SOLSOL-1.82%coin-img-USDCUSDC+0.02%coin-img-UBOXUBOX+2,026.66%coin-img-XRPXRP+0.28%coin-img-TRXTRX+0.70%coin-img-HYPEHYPE-1.99%coin-img-ETHETH-1.67%coin-img-BTCBTC-0.32%coin-img-SOLSOL-1.82%coin-img-USDCUSDC+0.02%coin-img-UBOXUBOX+2,026.66%coin-img-XRPXRP+0.28%coin-img-TRXTRX+0.70%coin-img-HYPEHYPE-1.99%coin-img-ETHETH-1.67%coin-img-BTCBTC-0.32%coin-img-SOLSOL-1.82%coin-img-USDCUSDC+0.02%coin-img-UBOXUBOX+2,026.66%coin-img-XRPXRP+0.28%coin-img-TRXTRX+0.70%coin-img-HYPEHYPE-1.99%coin-img-ETHETH-1.67%coin-img-BTCBTC-0.32%coin-img-SOLSOL-1.82%coin-img-USDCUSDC+0.02%coin-img-UBOXUBOX+2,026.66%coin-img-XRPXRP+0.28%coin-img-TRXTRX+0.70%coin-img-HYPEHYPE-1.99%
user-avatar
Benzinga

Boston Scientific lowers fiscal 2026 outlook as Watchman and EP markets face pressure

AI Market Summary
Boston Scientific's Q2 beat on revenue and adjusted EPS was overshadowed by a fiscal 2026 guide cut, citing an unexpected slowdown in the Watchman U.S. market and sharper-than-expected competitive share losses in electrophysiology. Lower sales and EPS ranges compress the forward growth narrative and raise execution risk. A restructuring plan signals cost discipline but underscores near-term pressure on margins and demand visibility.
Impact level
● Medium
Affected assets
NCSKBSX2USD/USDT-0.34%
AI Insight · NCSKBSX2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Boston Scientific reported second-quarter revenue of $5.442 billion and adjusted earnings of 86 cents per share, topping expectations. At the same time, the company cut its fiscal 2026 revenue and profit guidance, citing slower momentum for its Watchman heart implant and intensifying competition in the U.S. electrophysiology (EP) market. The updated outlook calls for 2026 sales of $21.178 billion$21.379 billion and adjusted EPS of $3.28$3.32, down from prior targets.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.